-
1
-
-
34247483998
-
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study
-
Fox, C.S., S. Coady, P.D. Sorlie, et al. 2007. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115: 1544-1550.
-
(2007)
Circulation
, vol.115
, pp. 1544-1550
-
-
Fox, C.S.1
Coady, S.2
Sorlie, P.D.3
-
2
-
-
0032511566
-
-
UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352
-
UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352: 854-865.
-
-
-
-
3
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes
-
The ADVANCE Collaborative Group.
-
The ADVANCE Collaborative Group. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N. Engl. J. Med. 358: 2560-2572.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2560-2572
-
-
-
4
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 Diabetes
-
The Action to Control Cardiovascular Risk in Diabetes Study Group.
-
The Action to Control Cardiovascular Risk in Diabetes Study Group. 2008. Effects of intensive glucose lowering in type 2 Diabetes. N. Engl. J. Med. 358: 2545-2559.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2545-2559
-
-
-
5
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
VADT Investigators.
-
Duckworth, W., C. Abraira, T. Moritz, et al.; VADT Investigators. 2009. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360: 129-139.
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
6
-
-
79960959816
-
Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials
-
Boussageon, R., T. Bejan-Angoulvant, M. Saadatian-Elahi, et al. 2011. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 343: d4169.
-
(2011)
BMJ
, vol.343
-
-
Boussageon, R.1
Bejan-Angoulvant, T.2
Saadatian-Elahi, M.3
-
7
-
-
65649106228
-
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
-
Ray, K.K., S.R. Seshasai, S. Wijesuriya, et al. 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-1772.
-
(2009)
Lancet
, vol.373
, pp. 1765-1772
-
-
Ray, K.K.1
Seshasai, S.R.2
Wijesuriya, S.3
-
8
-
-
70349881450
-
Intensive glucose control and macrovascular outcomes in type 2 diabetes
-
Control Group.
-
Turnbull, F.M, C. Abraira, R.J. Anderson, et al.; Control Group. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52: 2288-2298.
-
(2009)
Diabetologia
, vol.52
, pp. 2288-2298
-
-
Turnbull, F.M.1
Abraira, C.2
Anderson, R.J.3
-
9
-
-
82755165018
-
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
-
Hemmingsen, B., S.S. Lund, C. Gluud, et al. 2011. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898.
-
(2011)
BMJ
, vol.343
-
-
Hemmingsen, B.1
Lund, S.S.2
Gluud, C.3
-
10
-
-
84957415695
-
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
-
Hemmingsen, B., S.S. Lund, C. Gluud, et al. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane. Database Syst. Rev. 6: CD008143.
-
(2011)
Cochrane. Database Syst. Rev.
, Issue.6
-
-
Hemmingsen, B.1
Lund, S.S.2
Gluud, C.3
-
11
-
-
0037472879
-
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
-
Gaede, P., P. Vedel, N. Larsen, et al. 2003. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348: 383-393.
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 383-393
-
-
Gaede, P.1
Vedel, P.2
Larsen, N.3
-
12
-
-
38949210220
-
Effect of a multifactorial intervention on mortality in type 2 diabetes
-
Gaede, P., H. Lund-Andersen, H.H. Parving & O. Pedersen. 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358: 580-591.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 580-591
-
-
Gaede, P.1
Lund-Andersen, H.2
Parving, H.H.3
Pedersen, O.4
-
13
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
ACCORD Study Group.
-
Cushman, W.C., G.W. Evans, R.P. Byington, et al.; ACCORD Study Group. 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1575-1585.
-
(2010)
N. Engl. J. Med.
, vol.362
, pp. 1575-1585
-
-
Cushman, W.C.1
Evans, G.W.2
Byington, R.P.3
-
14
-
-
34548420712
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
-
ADVANCE Collaborative Group.
-
Patel, A., S. MacMahon, J. Chalmers, et al. ADVANCE Collaborative Group. 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
-
(2007)
Lancet
, vol.370
, pp. 829-840
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
-
15
-
-
77954374543
-
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
-
Cooper-DeHoff, R.M., Y. Gong, E.M. Handberg, et al. 2010. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304: 61-68.
-
(2010)
JAMA
, vol.304
, pp. 61-68
-
-
Cooper-DeHoff, R.M.1
Gong, Y.2
Handberg, E.M.3
-
16
-
-
79951713554
-
Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial
-
VADT Study Group.
-
Anderson, R.J., G.D. Bahn, T.E. Moritz, et al.; VADT Study Group. 2011. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 34: 34-38.
-
(2011)
Diabetes Care
, vol.34
, pp. 34-38
-
-
Anderson, R.J.1
Bahn, G.D.2
Moritz, T.E.3
-
17
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group.
-
Ginsberg, H.N., M.B. Elam, L.C. Lovato, et al.; ACCORD Study Group. 2010. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1563-1574.
-
(2010)
N. Engl. J. Med.
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
18
-
-
77953069181
-
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
-
Epub 2010 Jan 26].
-
Calles-Escandón, J., L.C. Lovato, D.G. Simons-Morton, et al. 2010. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33: 721-727. [Epub 2010 Jan 26].
-
(2010)
Diabetes Care
, vol.33
, pp. 721-727
-
-
Calles-Escandón, J.1
Lovato, L.C.2
Simons-Morton, D.G.3
-
19
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman, R.R., S.K. Paul, M.A. Bethel, et al. 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359: 1577-1589.
-
(2008)
N Engl J Med.
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
-
20
-
-
84856255697
-
Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes
-
Tandon, N., M.K. Ali & K.M. Narayan. 2012. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 12: 7-22.
-
(2012)
Am J Cardiovasc Drugs
, vol.12
, pp. 7-22
-
-
Tandon, N.1
Ali, M.K.2
Narayan, K.M.3
-
21
-
-
63149103614
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
-
American Diabetes Association; American College of Cardiology Foundation; American Heart Association.
-
Skyler, J.S., R. Bergenstal, R.O. Bonow, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. 2009. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32: 187-192.
-
(2009)
Diabetes Care
, vol.32
, pp. 187-192
-
-
Skyler, J.S.1
Bergenstal, R.2
Bonow, R.O.3
-
22
-
-
71049118192
-
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.
-
Veterans Affairs Diabetes Trial.
-
Reaven, P.D., T.E. Moritz, D.C. Schwenke, et al.; Veterans Affairs Diabetes Trial. 2009. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58: 2642-2648.
-
(2009)
Diabetes
, vol.58
, pp. 2642-2648
-
-
Reaven, P.D.1
Moritz, T.E.2
Schwenke, D.C.3
-
23
-
-
79951691814
-
Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT)
-
on behalf of the Veterans Affairs Diabetes Trial (VADT).
-
Saremi, A., T.E. Moritz, R.J. Anderson, et al., on behalf of the Veterans Affairs Diabetes Trial (VADT). 2010. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 33: 2642-2647.
-
(2010)
Diabetes Care
, vol.33
, pp. 2642-2647
-
-
Saremi, A.1
Moritz, T.E.2
Anderson, R.J.3
-
24
-
-
84855185039
-
Standards of medical care in diabetes-2012
-
American Diabetes Association.
-
American Diabetes Association. 2012. Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl. 1): S11-S63.
-
(2012)
Diabetes Care
, vol.35
, Issue.SUPPL. 1
-
-
-
25
-
-
77954159481
-
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
-
for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators.
-
Riddle, M.C., W.T. Ambrosius, D.J. Brillon, et al., for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. 2010. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33: 983-990.
-
(2010)
Diabetes Care
, vol.33
, pp. 983-990
-
-
Riddle, M.C.1
Ambrosius, W.T.2
Brillon, D.J.3
-
26
-
-
84864285795
-
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi, S.E., R.M. Bergenstal, J.B. Buse, et al. 2012. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
-
(2012)
Diabetologia
, vol.55
, pp. 1577-1596
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
27
-
-
78650122448
-
Defining and achieving treatment success in patients with type 2 diabetes mellitus
-
Stolar, M.W. 2010. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo. Clin. Proc. 85(12 Suppl): S50-S59.
-
(2010)
Mayo. Clin. Proc.
, vol.85
, Issue.12 SUPPL
-
-
Stolar, M.W.1
-
28
-
-
33646422782
-
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
-
Evans, J.M., S.A. Ogston, A. Emslie-Smith & A.D. Morris. 2006. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49: 930-936.
-
(2006)
Diabetologia
, vol.49
, pp. 930-936
-
-
Evans, J.M.1
Ogston, S.A.2
Emslie-Smith, A.3
Morris, A.D.4
-
29
-
-
0141989681
-
Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA)
-
Meier, J.J., S. Deifuss, A. Klamann, et al. 2003. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp. Clin. Endocrinol. Diabetes 111: 344-350.
-
(2003)
Exp. Clin. Endocrinol. Diabetes
, vol.111
, pp. 344-350
-
-
Meier, J.J.1
Deifuss, S.2
Klamann, A.3
-
30
-
-
77955285732
-
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
-
Nissen, S.E. & K. Wolski. 2010. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170: 1191-1201.
-
(2010)
Arch. Intern. Med.
, vol.170
, pp. 1191-1201
-
-
Nissen, S.E.1
Wolski, K.2
-
31
-
-
79953203593
-
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
-
Loke, Y.K., C.S. Kwok & S. Singh. 2011. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309.
-
(2011)
BMJ
, vol.342
-
-
Loke, Y.K.1
Kwok, C.S.2
Singh, S.3
-
32
-
-
34548590934
-
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials
-
Lincoff, A.M., K. Wolski, S.J. Nicholls & S.E. Nissen. 2007. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 298: 1180-1188.
-
(2007)
JAMA
, vol.298
, pp. 1180-1188
-
-
Lincoff, A.M.1
Wolski, K.2
Nicholls, S.J.3
Nissen, S.E.4
-
33
-
-
0041322547
-
Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study
-
Winkler, K., T. Konrad, S. Füllert, et al. 2003. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26: 2588-2594.
-
(2003)
Diabetes Care
, vol.26
, pp. 2588-2594
-
-
Winkler, K.1
Konrad, T.2
Füllert, S.3
-
34
-
-
20444495375
-
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study
-
Pfützner, A., N. Marx, G. Lübben, et al. 2005. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45: 1925-1931.
-
(2005)
J. Am. Coll. Cardiol.
, vol.45
, pp. 1925-1931
-
-
Pfützner, A.1
Marx, N.2
Lübben, G.3
-
35
-
-
33745834319
-
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
-
Kadowaki, T., T. Yamauchi, N. Kubota, et al. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116: 1784-1792.
-
(2006)
J. Clin. Invest.
, vol.116
, pp. 1784-1792
-
-
Kadowaki, T.1
Yamauchi, T.2
Kubota, N.3
-
36
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study
-
PROactive investigators.
-
Dormandy, J.A., B. Charbonnel, D.J. Eckland, et al.; PROactive investigators. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet 366: 1279-1289.
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
37
-
-
53349153475
-
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
-
Mannucci, E., M. Monami, C. Lamanna, et al. 2008. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 10: 1221-1238.
-
(2008)
Diabetes Obes. Metab.
, vol.10
, pp. 1221-1238
-
-
Mannucci, E.1
Monami, M.2
Lamanna, C.3
-
38
-
-
77958529709
-
Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?
-
Schernthaner, G. & R.J. Chilton. 2010. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes. Metab. 12: 1023-1035.
-
(2010)
Diabetes Obes. Metab.
, vol.12
, pp. 1023-1035
-
-
Schernthaner, G.1
Chilton, R.J.2
-
39
-
-
33847675510
-
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study
-
PROactive Investigators.
-
Erdmann, E., J.A. Dormandy, B. Charbonnel, et al.; PROactive Investigators. 2007. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49: 1772-1780.
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
, pp. 1772-1780
-
-
Erdmann, E.1
Dormandy, J.A.2
Charbonnel, B.3
-
40
-
-
33746218171
-
Is insulin resistance atherogenic? Possible mechanisms
-
De Fronzo, R.A. 2006. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl. 7: 11-15.
-
(2006)
Atheroscler Suppl.
, vol.7
, pp. 11-15
-
-
De Fronzo, R.A.1
-
41
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group.
-
UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
43
-
-
79955397107
-
Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies
-
Giorgino, F., A. Leonardini, A. Natalicchio & L. Laviola. 2011. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J. Endocrinol. Invest. 34: 69-77.
-
(2011)
J. Endocrinol. Invest.
, vol.34
, pp. 69-77
-
-
Giorgino, F.1
Leonardini, A.2
Natalicchio, A.3
Laviola, L.4
-
44
-
-
66249138889
-
Glucagon-like peptide-1 and myocardial protection: more than glycemic control
-
Fields, A.V., B. Patterson, A.A. Karnik & R.P. Shannon. 2009. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin. Cardiol. 32: 236-243.
-
(2009)
Clin. Cardiol.
, vol.32
, pp. 236-243
-
-
Fields, A.V.1
Patterson, B.2
Karnik, A.A.3
Shannon, R.P.4
-
45
-
-
2942668372
-
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
-
Gutzwiller, J.P., S. Tschopp, A. Bock, et al. 2004. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89: 3055-3061.
-
(2004)
J. Clin. Endocrinol. Metab.
, vol.89
, pp. 3055-3061
-
-
Gutzwiller, J.P.1
Tschopp, S.2
Bock, A.3
-
46
-
-
53649083746
-
The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance
-
Nyström, T. 2008. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 40: 593-606.
-
(2008)
Horm. Metab. Res.
, vol.40
, pp. 593-606
-
-
Nyström, T.1
-
47
-
-
50649110233
-
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
-
Courrèges, J.P., T. Vilsbøll, M. Zdravkovic, et al. 2008. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25: 1129-1131.
-
(2008)
Diabet. Med.
, vol.25
, pp. 1129-1131
-
-
Courrèges, J.P.1
Vilsbøll, T.2
Zdravkovic, M.3
-
48
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis, L.A., S. Mankad, G.G. Sokos, et al. 2004. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965.
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
-
49
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
Sokos, G.G., L.A. Nikolaidis, S. Mankad, et al. 2006. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12: 694-699.
-
(2006)
J. Card. Fail.
, vol.12
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
-
50
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
Bose, A.K., M.M. Mocanu, R.D. Carr, et al. 2005. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151.
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
-
51
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
Timmers, L., J.P. Henriques, D.P. de Kleijn, et al. 2009. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53: 501-510.
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, pp. 501-510
-
-
Timmers, L.1
Henriques, J.P.2
de Kleijn, D.P.3
-
52
-
-
64649102619
-
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
-
Noyan-Ashraf, M.H., M.A. Momen, K. Ban, et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
-
(2009)
Diabetes
, vol.58
, pp. 975-983
-
-
Noyan-Ashraf, M.H.1
Momen, M.A.2
Ban, K.3
-
53
-
-
84870161013
-
Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway
-
Laviola, L., A. Leonardini, M. Melchiorre, et al. 2012. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology 153: 5770-5781.
-
(2012)
Endocrinology
, vol.153
, pp. 5770-5781
-
-
Laviola, L.1
Leonardini, A.2
Melchiorre, M.3
-
54
-
-
84860204551
-
Cardiovascular biology of the incretin system
-
Ussher, J.R. & D.J. Drucker. 2012. Cardiovascular biology of the incretin system. Endocr. Rev. 33: 187-215.
-
(2012)
Endocr. Rev.
, vol.33
, pp. 187-215
-
-
Ussher, J.R.1
Drucker, D.J.2
-
55
-
-
41849099939
-
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
-
Mistry, G.C., A.L. Maes, K.C. Lasseter, et al. 2008. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol. 48: 592-598.
-
(2008)
J. Clin. Pharmacol.
, vol.48
, pp. 592-598
-
-
Mistry, G.C.1
Maes, A.L.2
Lasseter, K.C.3
-
56
-
-
33847024333
-
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
-
Scott, R., M. Wu, M. Sanchez & P. Stein. 2007. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61: 171-180.
-
(2007)
Int. J. Clin. Pract.
, vol.61
, pp. 171-180
-
-
Scott, R.1
Wu, M.2
Sanchez, M.3
Stein, P.4
-
57
-
-
77956069166
-
Hypoglycemia, diabetes and cardiovascular events
-
Desouza, C.V., G.B. Bolli & V. Fonseca. 2010. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care 33: 1389-1394.
-
(2010)
Diabetes Care
, vol.33
, pp. 1389-1394
-
-
Desouza, C.V.1
Bolli, G.B.2
Fonseca, V.3
-
58
-
-
80052615073
-
Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review
-
Noh, R.M., A.J. Graveling & B.M. Frier. 2011. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opin. Pharmacother. 12: 2161-2175.
-
(2011)
Expert Opin. Pharmacother.
, vol.12
, pp. 2161-2175
-
-
Noh, R.M.1
Graveling, A.J.2
Frier, B.M.3
-
59
-
-
0032875210
-
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
-
Landstedt-Hallin, L., A. Englund, U. Adamson & P.E. Lins. 1999. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J. Intern. Med. 246: 299-307.
-
(1999)
J. Intern. Med.
, vol.246
, pp. 299-307
-
-
Landstedt-Hallin, L.1
Englund, A.2
Adamson, U.3
Lins, P.E.4
-
61
-
-
74949117631
-
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
-
doi: 10.1136/bmj.b4909.
-
Bonds, D.E., M.E. Miller, R.M. Bergenstal, et al. 2010. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340: b4909. doi: 10.1136/bmj.b4909.
-
(2010)
BMJ
, vol.340
-
-
Bonds, D.E.1
Miller, M.E.2
Bergenstal, R.M.3
-
62
-
-
79952273819
-
Long-term effects of intensive glucose lowering on cardiovascular outcomes
-
ACCORD Study Group.
-
Gerstein, H.C., M.E. Miller, S. Genuth, et al.; ACCORD Study Group. 2011. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364: 818-828.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 818-828
-
-
Gerstein, H.C.1
Miller, M.E.2
Genuth, S.3
-
63
-
-
77957742069
-
Severe hypoglycemia and risks of vascular events and death
-
ADVANCE Collaborative Group.
-
Zoungas, S., A. Patel, J. Chalmers, et al.; ADVANCE Collaborative Group. 2010. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363: 1410-1418.
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1410-1418
-
-
Zoungas, S.1
Patel, A.2
Chalmers, J.3
-
64
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group.
-
UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
|